FeesSafety
Pluang+

Polen International Small Cap Equity outperforms MSCI ACWI ex-US Small Cap Index with 2.70% return in Q3 2026

04 Nov 2026, 14:50 WIB
Seeking Alpha
View Source
Neutral
Polen International Small Cap Equity outperforms MSCI ACWI ex-US Small Cap Index with 2.70% return in Q3 2026

In Q3 2026, the Polen International Small Cap Equity Composite Portfolio delivered a 2.70% gross return, outperforming the MSCI ACWI ex-US Small Cap Index. Key contributors to the portfolio's gains included Happinet, Hokuhoku Financial Group, and Nippon Avionics, while Mitsui Kinzoku, Pfisterer Holding, and Nextage were the largest detractors. Polen Capital continues to focus on high conviction, quality growth investments with the potential for long-term outperformance. This performance highlights the portfolio's strength in navigating international small-cap markets.

The Polen International Small Cap Equity Q3 2026 Portfolio Update is provided here as market context. For readers following Financials-sector US stocks on Pluang, as of Nov 04, 2026 19:31 WIB, out of 142 priced stocks, 110 rose and 31 fell. Notable movers include SAN (Banco Santander SA) at USD 12.08 with a 1-day change of +6.53% and 100% buy order activity, DB (Deutsche Bank AG) at USD 36.23 with a +6.46% change and 100% sell order activity, and BBVA (Banco Bilbao Vizcaya Argentaria SA) at USD 25.36 with a +5.67% change and 100% sell order activity.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
26 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
26 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
26 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
26 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
26 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App